RxDoctor Payments Data

Shadi Qasqas, MD

Interventional Cardiology · Rancho Cucamonga, CANPI 1740498328

Payments from drug & device makers

$7,359in general payments, 2019–2025

Across 290 payments — averaging $25.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Abiomed$954
  • Penumbra, Inc.$930
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$912
  • Novartis$555
  • Boston Scientific$425
  • plus $2K from 25 others

What the payments were for

  • Travel & lodging$84111%
  • Food & beverage$6,44988%
  • Education$701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,359 in reported general payments places this provider in the 40th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$1,028,901
Medicare patients
1,082
Services billed
9,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban222$237,897
EntrestoSacubitril/Valsartan117$127,096
FarxigaDapagliflozin Propanediol75$66,258
XareltoRivaroxaban36$35,627
VerquvoVericiguat39$31,726
JardianceEmpagliflozin26$30,680
MultaqDronedarone Hcl16$24,821
BrilintaTicagrelor37$22,735
Repatha SureclickEvolocumab31$21,615
DapagliflozinDapagliflozin Propanediol22$18,438
Metoprolol Succinate167$3,550
Ranolazine ErRanolazine64$3,431
Atorvastatin Calcium283$3,256
Nifedipine ErNifedipine49$2,515
Amiodarone Hcl74$2,506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$173$237,897222 claims
NovartisEntresto$555$127,096117 claims
AstraZenecaFarxiga, Brilinta$222$88,992112 claims
Johnson & JohnsonXarelto$129$35,62736 claims
MerckVerquvo$396$31,72639 claims
Boehringer IngelheimJardiance$38$30,68026 claims
Sanofi-aventis U.S. LLCMultaq$140$24,82116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Rancho Cucamonga

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →